Key facts
- SynchNeuro’s last known valuation is $13.0M (Aug 2025).
- It has raised $6.0M; the latest was Accelerator/Incubator in Oct 2025.
- Notable investors include Plug and Play Tech Center, MedTech Innovator, Acequia Capital, Boomerang Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for SynchNeuro
- ·The full record, as it builds
Funding rounds
No funding rounds for SynchNeuro are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SynchNeuro
Developer of non-invasive brain-signal-based wearable monitoring technology intended to track metabolic and physiological health metrics. The company platform offers behind the ear electroencephalogram, signal analysis software, continuous glucose-trend estimation, sleep-quality assessment features, and metabolic-state monitoring tools, enabling living individuals seeking accessible, needle-free wellness tracking to gain real-time insight into glucose patterns, sleep behaviors, stress indicators, and broader cardiometabolic health for proactive personal health management.
- Sector
- Healthcare
- HQ
- Philadelphia, PA, United States
- Founded
- 2021
- Employees
- 7
- Website
- synchneuro.com/
- Ownership
- Privately Held (backing)
SynchNeuro doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SynchNeuro shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SynchNeuro in its N-PORT filings yet. We sweep new filings monthly.